Research programme: cancer therapeutics - Breakpoint Therapeutics
Latest Information Update: 28 Jan 2026
At a glance
- Originator Evotec
- Developer Breakpoint Therapeutics
- Class Antineoplastics
- Mechanism of Action DNA repair inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for research development in Cancer in Germany
- 18 Jan 2024 Early research in Cancer is ongoing Germany
- 28 Aug 2023 No recent reports of development identified for research development in Cancer in Germany